logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

GlaxoSmithKline and Vir Biotechnology Announce EUA from the US FDA for Sotrovimab in Treating Mild-to-Moderate COVID-19

GlaxoSmithKline and Vir Biotechnology are Granted an EUA for Sotrovimab GlaxoSmithKline ( GSK ) and Vir Biotechnology ( VIR ) announced the U.S. FDA has granted an Emergency Use Authorization ( EUA ) for sotrovimab (formerly VIR-7831) - an investigational...

Read More

May 27, 2021

0

The World Health Organization Recommends Regeneron Pharmaceuticals Antibody Cocktail for COVID-19

Regeneron Welcomes the World Health Organization's Recommendation for Use of REGEN- COVTM to Treat COVID-19 The World Health Organization ( WHO ) updated its Therapeutics and COVID-19: living guideline to include the casirivimab and imdevimab monoclonal antibody cocktail, known as...

Read More

September 24, 2021

0

Moderna Speeding Towards Delivering the Awaited Novel Coronavirus Prophylactic Vaccine

Moderna mRNA-1273 Vaccine for COVID-19  The market is expected to open DOWN today. Moderna’s ( MRNA ) stock price, however, is expected to post gains as news coming from the company is highly encouraging. Moderna announced progress on the late-stage...

Read More

June 11, 2020

0

Amgen: FDA Approves LUMAKRAS™, the First and Only Targeted Treatment for Patients with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

Amgen Announced FDA Approval of LUMAKRAS ™   Amgen ( AMGN ) announced the news about the FDA approval of LUMAKRAS™ (sotorasib) on May 28, 2021. The firm indicated that the FDA granted approval is for adults with KRAS G12C-mutated locally...

Read More

May 31, 2021

0

Why Merck KGaA, Darmstadt, Germany Paid Sutro Biopharma. See Also: BMY Approval of Zeposia for UC

Sutro Biopharma Receives Milestone Payment from Merck KGaA, Darmstadt, Germany Sutro Biopharma ( STRO ) announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt,Germany . The payment...

Read More

June 1, 2021

0

Illumina's COVIDSeq Test Granted Emergency Use Authorization. See Also: CRISPR Therapeutics and Vertex Encouraging News

Illumina Diagnostic Test COVIDSeq to Detect SARS-CoV-2 Illumina ( ILMN ) was issued an Emergency Use Authorization ( EUA ) from the FDA for the first COVID-19 diagnostic test utilizing next-generation sequence technology. The authorization was granted for the Illumina...

Read More

June 15, 2020

0

Valneva SE and Pfizer Inc Announce Further Positive Results in Preventing Lyme Disease 

Valneva SE and Pfizer Inc Announced More Positive Trial Results of VLA15 for Lyme Disease What is Lyme Disease? What is the vaccine? What is the importance of the vaccine and the company that created it?    Lyme disease is...

Read More

September 30, 2021

0

Good News for Four Companies: Jazz, Celldex, Inventiva & Illumina

Good News for Jazz, Celldex, Inventiva & Illumina Jazz Pharmaceuticals Good News Jazz Pharmaceuticals ( JAZZ ) announced along with its partner  PharmaMar (MSE: PHM ) that the U.S. FDA has approved Zepzelca™ (lurbinectedin) for adults with metastatic small cell lung cancer ( SCLC...

Read More

June 17, 2020

0

Merck and Ridgeback Biotherapeutics Announced Successful Phase 3 Trial Results of Molnupiravir for Mild or Moderate COVID-19

Merck and Ridgeback Biotherapeutics COVID-19 News  Merck ( MRK )  and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801) - an investigational oral antiviral medicine, has significantly reduced the risk of hospitalization or death at a planned interim analysis of the...

Read More

October 1, 2021

0

Atea Pharmaceuticals and Xenon Pharmaceuticals: Two Clinical-Stage Firms That Rallied Instead of Crashing Yesterday

Two Clinical-Stage Firms Rallied Yesterday On a day when the Stock Market was crushed, taking down with it shareholders’ money for no reason other than the self-serving untouchable agendas, two small biotechnology companies staged rallies. Atea Pharmaceuticals and Xenon Pharmaceuticals...

Read More

October 5, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 24
  • 25
  • 26
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy